Aridol

Overview

Pharmaxis' first commercial product, Aridol is an innovative lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness.

By having patients inhale Aridol via a simple hand-held device, doctors can determine the severity of a patient's inflammation and prescribe the right amount of medication to bring it under control. The Aridol challenge test potentially prevents inappropriate treatment and may help patients better comply with their therapies.

Aridol is approved for sale in Australia, major European countries, Korea and Pharmaxis has filed a New Drug Application (NDA) for the approval of Aridol in the United States. It is the first and only approved Europe-wide lung function test and the world's first approved indirect challenge test for asthma, a condition which affects 52 millions people worldwide.

Aridol is involved in investigator-sponsored clinical trials worldwide, treating thousand of patients. It has also been included in both international and Australian official guidelines for managing asthma — recognition and endorsement by both global and Australian experts that Aridol is a significant addition to the tools available to help asthma patients. Bodies and guidelines endorsing Aridol include:

International Olympic Committee Medical Commission's Independent Panel
US Asthma Management Guidelines
Global Initiative for Asthma (GINA) Report on Global Strategy for Asthma Management and Prevention
World Anti-Doping Agency
Australian Asthma Management Handbook

Recent Aridol Milestones

Aridol launched in 12 European countries and Korea using distribution partners
New Drug Application accepted for review by the United States FDA
Presentations at American Thoracic Society international conference

Upcoming Aridol Events

Response from FDA on Aridol New Drug Application
Aridol to launch in Korea and Germany

Aridol home page

PAGE CONTENTS

Current clinical trials